Back to search

Article

Real-World Outcomes of Subcutaneous PHESGO® in HER2-Positive Breast Cancer: Pathological Response, Se-Quencing, and Safety

2025-11-18

Abstract excerpt

<h4>Background: </h4> Subcutaneous pertuzumab and trastuzumab with hyaluronidase (PHESGO®) shortens chair time versus intravenous dual HER2 blockade, but Asian real-world data are scarce. <h4>Methods:</h4> We retrospectively reviewed 47 Asian patients with HER2-positive breast cancer treated with PHESGO® (January 2024–July 2025) across neoadjuvant, adjuvant, and metastatic settings. The primary endpoint was pathol...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
647995e8-a600-5520-8770-d0d00de3bdcb
DOI
10.20944/preprints202511.1222.v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Real-World Outcomes of Subcutaneous PHESGO® in HER2-Positive Breast Cancer: Pathological Response, Se-Quencing, and SafetyDOI 10.20944/preprints202511.1222.v1
The Efficacy and Safety of Sacituzumab Govitecan in Heavily Pretreated Metastatic Triple-Negative and Hormone Receptor-Positive/HER2-Negative Breast Cancer: A Multicenter Real-World Study from TurkeySemantic proximity
Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2-Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2-Expressing or Mutated Advanced Solid Tumors: A Global Phase I Trial.Semantic proximity
Post–CDK4/6 Inhibitor Therapeutic Approaches in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Current Evidence and Emerging Strategies - A Narrative ReviewSemantic proximity
Comparison of Targeted Therapy Efficacy in HER2-Positive Versus HER2-Negative Breast Cancer PatientsSemantic proximity
Adverse event profile differences between Trastuzumab Emtansine and Trastuzumab Deruxtecan: a real-world, pharmacovigilance studySemantic proximity
Efficacy and Safety of the use of Pertuzumab in Metastatic Breast Cancer Patients in a Real-World Setting: Results from the SUPER-GONO (Gruppo Oncologico del Nord Ovest) StudySemantic proximity
Systemic and Intracranial Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Mutant NSCLC Across Treatment Lines: Evidence From the TRACER/HERTras Real-World Cohort.Semantic proximity
Phase II Exploratory Study of Neoadjuvant Disitamab Vedotin and Penpulimab in HER2-low Stage II-III Breast Cancer (NeoPanDa04)Semantic proximity
A signal-seeking phase 2 study of Trastuzumab emtansine in tumours harbouring HER2 amplification or mutationSemantic proximity
[Recent Advances in the Treatment of HER2-Altered Solid Tumors].Semantic proximity
Real-World Treatment Patterns and Outcomes in Elderly Patients with Metastatic Breast Cancer: A Multi- institutional Retrospective Cohort StudySemantic proximity
Clinical Potential of Antibody–Drug Conjugates in Early-Phase Clinical Trials for Late-Line Treatment of Advanced Solid TumorsSemantic proximity
Select a neighboring publication to make it the new centre.